We are live on ! Find out more
TSHA icon

Taysha Gene Therapies
TSHA

150 hedge funds and large institutions have $595M invested in Taysha Gene Therapies in 2025 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

889% more call options, than puts

Call options by funds: $465K | Put options by funds: $47K

157% more capital invested

Capital invested by funds: $232M → $595M (+$363M)

120% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

41% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 34

38.66% more ownership

Funds ownership: 81.39% → 120.06% (+39%)

18% more funds holding

Funds holding: 127 → 150 (+23)

Holders
150
Holders Change
+23
Holders Change %
+18.11%
% of All Funds
1.97%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
44
Increased
48
Reduced
34
Closed
20
Calls
$465K
Puts
$47K
Net Calls
+$418K
Net Calls Change
+$281K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$27.6M
2
Goldman Sachs
Goldman Sachs
New York
+$26.6M
3
JFG
Jefferies Financial Group
New York
+$21.9M
4
RI
RTW Investments
New York
+$13.5M
5
DM
Deerfield Management
New York
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$1.7M
2
GIM
Granahan Investment Management
Massachusetts
-$1.48M
3
SCM
Superstring Capital Management
New York
-$1.05M
4
DCM
DAFNA Capital Management
California
-$726K
5
BlackRock
BlackRock
New York
-$620K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$57.8M +$13.5M +6,233,718 +33%
RCM
2
RA Capital Management
Massachusetts
$54.4M +$27.6M +12,683,145 +117%
ACA
3
Avoro Capital Advisors
New York
$50.1M +$3.69M +1,700,001 +9%
Morgan Stanley
4
Morgan Stanley
New York
$39M +$40.6K +18,708 +0.1%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$36.1M -$8.98K -4,132 -0%
BlackRock
6
BlackRock
New York
$30.7M -$620K -285,403 -2%
OCA
7
Octagon Capital Advisors
New York
$29.1M +$4.11M +1,892,500 +18%
Goldman Sachs
8
Goldman Sachs
New York
$29.1M +$26.6M +12,228,693 +3,406%
SL
9
Siren LLC
Connecticut
$25.4M +$9.78M +4,500,000 +69%
Vanguard Group
10
Vanguard Group
Pennsylvania
$25.2M +$4.61M +2,123,206 +24%
JFG
11
Jefferies Financial Group
New York
$23.8M +$21.9M +10,068,479 +4,105%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$16.9M +$5.97M +2,747,936 +60%
DM
13
Deerfield Management
New York
$12.4M +$11.7M +5,386,000 New
State Street
14
State Street
Massachusetts
$11.9M +$4.14M +1,904,798 +59%
PCH
15
Polar Capital Holdings
United Kingdom
$11.6M +$4.35M +2,000,000 +67%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$11.2M +$10.5M +4,839,000 New
Toronto Dominion Bank
17
Toronto Dominion Bank
Ontario, Canada
$10.9M +$10.3M +4,728,806 New
TCM
18
Tybourne Capital Management
Hong Kong
$9.46M +$858K +395,000 +11%
BBA
19
Baker Bros. Advisors
New York
$9.25M – – –
Geode Capital Management
20
Geode Capital Management
Massachusetts
$8.77M +$280K +128,840 +4%
SCM
21
Suvretta Capital Management
New York
$7.43M +$6.99M +3,217,449 New
ACM
22
ADAR1 Capital Management
Texas
$6.95M +$4.22M +1,943,561 +182%
VPC
23
Vestal Point Capital
New York
$6.93M +$6.52M +3,000,000 New
MB
24
MPM BioImpact
Massachusetts
$6.82M +$6.42M +2,953,562 New
Millennium Management
25
Millennium Management
New York
$6.78M +$2.53M +1,163,074 +66%
1
2 3 4 5

TSHA Hedge Fund Activity: Q2 2025 in Review

150 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2025, worth a combined $595M — up 157% from $232M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new TSHA positions and 20 closed out — a net gain of 24 holders — while 48 added to existing stakes and 34 trimmed.

The largest buyer was RA Capital Management, adding an estimated $27.6M. The largest seller was JP Morgan Chase, cutting an estimated $1.7M.

  • 150 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2025, up from 127 in Q1 2025.
  • Funds reported $595M of Taysha Gene Therapies stock for Q2 2025, up 157% quarter-over-quarter.
  • 44 funds opened new Taysha Gene Therapies positions in Q2 2025 and 20 closed out, a net change of +24 holders.
  • The largest Taysha Gene Therapies buyer in Q2 2025 was RA Capital Management, an estimated $27.6M added.
  • The largest Taysha Gene Therapies seller in Q2 2025 was JP Morgan Chase, an estimated $1.7M sold.

Based on aggregated 13F filings for Q2 2025.